drugset

drugset / Trial / NCT00804947

Autologous Stem Cell Transplant (ASCT) With Intravenous Busulfan and Melphalan as Conditioning Regimen

NCT00804947 ↗

Phase 2 Unknown 50 enrolled Fundacion Para La Investigacion Hospital La Fe

NaSingle-groupOpen-labelTreatment

Summary

Analyze the results of ASCT using intravenous Busulfan and Melphalan as conditioning regimen for patients with Multiple Myeloma.

Timeline

Start: 2005-09
Primary completion: 2010-03
Completion: 2010-03

Publications

Blanes M, Lahuerta JJ, Gonzalez JD, Ribas P, Solano C, Alegre A, Blade J, San Miguel JF, Sanz MA, de la Rubia J. Intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a matched comparison to a melphalan-only approach. Biol Blood Marrow Transplant. 2013 Jan;19(1):69-74. doi: 10.1016/j.bbmt.2012.08.009. Epub 2012 Aug 13.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Busulfan	Small molecule	3.2 mg/kg	Intravenous
Subject	Melphalan	Small molecule	140 mg/m2	—

Indications